Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
4 minute read
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank

By Chris Katje
Today, 8:21 PM
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the company’s Silicon Valley Bank.

AMBA

Read More
1 minute read
  • News

IGM Biosciences Says Has Less Than $5M In Deposits At SVB

By Benzinga Newsdesk
Today, 8:21 PM
-SEC Filing

IGMS

Read More
2 minute read
  • Events
  • News
  • Small Cap

GM Biosciences Presented Data from T cell Engager Portfolio for Hematologic Malignancies at ASH 2022

By Charles Gross
Today, 8:21 PM
IGM Biosciences, Inc.

IGMS

Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday

By Lisa Levin
Today, 8:21 PM
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.

ACIU

Read More
2 minute read
  • Markets
  • Movers
  • News
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Unity Software, Amazon, Doximity And Other Big Gainers From Friday

By Lisa Levin
Today, 8:21 PM
U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session.

AA

Read More
6 minute read
  • Earnings
  • Markets
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday

By Lisa Levin
Today, 8:21 PM
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.

AA

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

HC Wainwright & Co. Maintains Buy on IGM Biosciences, Lowers Price Target to $45

By Benzinga Newsdesk
Today, 8:21 PM
HC Wainwright & Co. analyst Robert Burns maintains IGM Biosciences (NASDAQ:IGMS) with a Buy and lowers the price target from $58 to $45.

IGMS

Read More
1 minute read
  • Earnings

IGM Biosciences: Q3 Earnings Insights

By Benzinga Insights
Today, 8:21 PM
IGM Biosciences (NASDAQ:IGMS) reported its Q3 earnings results on Thursday, November 3, 2022 at 09:05 AM. Here's what investors need to know about the announcement.

IGMS

Read More
1 minute read
  • Biotech
  • General
  • News

IGM Biosciences And ADC Therapeutics Announce Clinical Collaboration Agreement To Evaluate Imvotamab In Combination With ZYNLONTA In Patients With Relapsed Or Refractory B Cell Non-Hodgkin’s Lymphoma

By Benzinga Newsdesk
Today, 8:21 PM
– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial

ADCT

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

JP Morgan Initiates Coverage On IGM Biosciences with Neutral Rating, Announces Price Target of $27

By Benzinga Newsdesk
Today, 8:21 PM
JP Morgan analyst Eric Joseph initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Neutral rating and announces Price Target of $27.

IGMS

Posts navigation

1 2 … 7 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service